Sinphar Pharmaceutical Co.,Ltd.
TWSE:1734.TW
32.4 (TWD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,962.934 | 2,856.651 | 2,433.516 | 2,388.452 | 2,394.589 | 2,215.837 | 2,134.163 | 2,133.511 | 2,187.401 | 2,642.145 | 2,577.907 | 2,086.627 | 1,840.266 | 1,822.648 | 1,813.468 |
| Cost of Revenue
| 1,871.691 | 1,765.351 | 1,544.809 | 1,512.919 | 1,453.744 | 1,390.455 | 1,323.904 | 1,343.598 | 1,401.418 | 1,558.519 | 1,613.625 | 1,314.617 | 1,146.463 | 1,128.481 | 1,089.574 |
| Gross Profit
| 1,091.243 | 1,091.3 | 888.707 | 875.533 | 940.845 | 825.382 | 810.259 | 789.913 | 785.983 | 1,083.626 | 964.282 | 772.01 | 693.803 | 694.167 | 723.894 |
| Gross Profit Ratio
| 0.368 | 0.382 | 0.365 | 0.367 | 0.393 | 0.372 | 0.38 | 0.37 | 0.359 | 0.41 | 0.374 | 0.37 | 0.377 | 0.381 | 0.399 |
| Reseach & Development Expenses
| 132.58 | 272.163 | 511.881 | 462.397 | 527.805 | 376.376 | 363.493 | 382.605 | 343.399 | 350.272 | 225.852 | 176.361 | 185.198 | 151.962 | 133.477 |
| General & Administrative Expenses
| 224.151 | 213.063 | 201.597 | 209.103 | 234.056 | 252.234 | 229.112 | 229.947 | 258.802 | 276.699 | 240.577 | 175.649 | 148.404 | 135.489 | 151.678 |
| Selling & Marketing Expenses
| 446.775 | 408.272 | 355.463 | 328.058 | 324.733 | 316.068 | 280.681 | 319.519 | 312.049 | 312.357 | 335.343 | 298.06 | 297.554 | 309.377 | 303.829 |
| SG&A
| 670.926 | 621.335 | 557.06 | 537.161 | 558.789 | 568.302 | 509.793 | 549.466 | 570.851 | 589.056 | 575.92 | 473.709 | 445.958 | 444.866 | 455.507 |
| Other Expenses
| -805.187 | 69.748 | 19.361 | 25.133 | 83.382 | 40.746 | 33.076 | 57.86 | 90.282 | 83.335 | 266.04 | 54.201 | 40.56 | 44.233 | 30.426 |
| Operating Expenses
| 805.187 | 893.498 | 1,068.941 | 999.558 | 1,086.594 | 944.678 | 873.286 | 932.071 | 914.25 | 939.328 | 801.772 | 650.07 | 631.156 | 596.828 | 588.984 |
| Operating Income
| 286.056 | 273.326 | -157.19 | -95.09 | -62.367 | -119.296 | -63.027 | -142.158 | -128.267 | 144.298 | 162.51 | 121.94 | 62.647 | 97.339 | 134.91 |
| Operating Income Ratio
| 0.097 | 0.096 | -0.065 | -0.04 | -0.026 | -0.054 | -0.03 | -0.067 | -0.059 | 0.055 | 0.063 | 0.058 | 0.034 | 0.053 | 0.074 |
| Total Other Income Expenses Net
| 19.652 | -28.28 | -27.335 | -22.683 | -24.339 | 31.615 | 10.216 | 107.234 | 69.608 | 63.067 | 247.479 | 23.337 | 26.83 | 26.159 | 6.344 |
| Income Before Tax
| 305.708 | 245.046 | -184.525 | -117.773 | -86.706 | -87.681 | -52.811 | -34.924 | -58.659 | 207.365 | 409.989 | 145.277 | 89.477 | 123.498 | 141.254 |
| Income Before Tax Ratio
| 0.103 | 0.086 | -0.076 | -0.049 | -0.036 | -0.04 | -0.025 | -0.016 | -0.027 | 0.078 | 0.159 | 0.07 | 0.049 | 0.068 | 0.078 |
| Income Tax Expense
| -51.068 | 80.872 | 20.434 | 54.786 | 61.216 | 35.324 | 37.355 | 29.249 | 24.87 | 108.406 | 85.254 | 37.799 | 25.552 | 21.1 | 28.915 |
| Net Income
| 375.17 | 164.174 | -204.959 | -172.559 | -147.922 | 8.785 | 36.726 | 16.545 | 13.952 | 163.393 | 300.691 | 121.304 | 72.229 | 110.93 | 131.034 |
| Net Income Ratio
| 0.127 | 0.057 | -0.084 | -0.072 | -0.062 | 0.004 | 0.017 | 0.008 | 0.006 | 0.062 | 0.117 | 0.058 | 0.039 | 0.061 | 0.072 |
| EPS
| 2.24 | 0.98 | -1.22 | -1.03 | -0.88 | 0.052 | 0.22 | 0.1 | 0.08 | 0.97 | 1.79 | 0.74 | 0.49 | 0.77 | 0.98 |
| EPS Diluted
| 2.23 | 0.98 | -1.22 | -1.03 | -0.88 | 0.052 | 0.22 | 0.1 | 0.08 | 0.97 | 1.79 | 0.74 | 0.48 | 0.76 | 0.9 |
| EBITDA
| 584.624 | 540.04 | 112.18 | 155.333 | 174.398 | 160.252 | 209.039 | 252.657 | 189.147 | 420.639 | 596.892 | 337.014 | 266.197 | 285.529 | 292.062 |
| EBITDA Ratio
| 0.197 | 0.189 | 0.046 | 0.065 | 0.073 | 0.072 | 0.098 | 0.118 | 0.086 | 0.159 | 0.232 | 0.162 | 0.145 | 0.157 | 0.161 |